Compare NEON & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | CVM |
|---|---|---|
| Founded | 1997 | 1983 |
| Country | Sweden | United States |
| Employees | N/A | 44 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 19.3M |
| IPO Year | 1994 | 1996 |
| Metric | NEON | CVM |
|---|---|---|
| Price | $1.70 | $2.31 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 84.5K | 63.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,108,000.00 | $264,033.00 |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.27 | $0.23 |
| 52 Week High | $29.90 | $13.48 |
| Indicator | NEON | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 29.63 |
| Support Level | $1.69 | N/A |
| Resistance Level | $1.74 | $4.84 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 88.57 | 1.85 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.